tiprankstipranks
Protara Therapeutics (TARA)
NASDAQ:TARA
US Market
TARA
Protara Therapeutics
RESEARCH TOOLSreports

Protara Therapeutics (TARA) Stock News & Sentiment

1,386 Followers
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
Premium
Company Announcements
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
13d ago
8K
TARA
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
Premium
Ratings
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
23d ago
TARA
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
Premium
Ratings
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
1M ago
TARA
TARA Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
TARA Upcoming Earnings Report: What to Expect?
1M ago
TARA
De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
Premium
Ratings
De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
1M ago
TARA
Protara Highlights Strong Phase 2 Data for TARA-002
Premium
Company Announcements
Protara Highlights Strong Phase 2 Data for TARA-002
2M ago
8K
TARA
Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
Premium
Ratings
Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
2M ago
TARA
More TARA News >

TARA News on the Web

Insider Sell: Jacqueline Zummo Sells Shares of Protara Therapeutics Inc (TARA)
GuruFocus News
Neutral
JPMorgan healthcare analysts hold an analyst/industry conference call
TipRanks News
Neutral
JonesTrading Remains a Buy on Protara Therapeutics (TARA)
TipRanks News
Neutral
Insider Sell: Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics Inc (TARA)
GuruFocus News
Neutral
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
TipRanks News
Neutral
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Neutral
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
TipRanks News
Bullish
J.P. Morgan Sticks to Its Buy Rating for Protara Therapeutics (TARA)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
TARA
Sector Average
Media Buzz
This Week3 articles
Weekly Average1.75 articles
News Sentiment
This Week50%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TARA’s Media Buzz Sentiment?
3 articles about TARA were published this week. In an average week, 1.75 articles are published.
    What is TARA’s weekly average amount of articles?
    In an average week, 1.75 articles about TARA are published.
      What is TARA’s News Sentiment?
      50% of articles about TARA were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week